<h2>Overview</h2>
<p>A three‑day intensive workshop titled “AI‑Driven Drug Discovery: Advanced Tools, Techniques & Applications” was held at the <span class="key-term" data-definition="Council of Scientific & Industrial Research — India’s premier R&D organization under the Ministry of Science & Technology (GS1: Institutions)">CSIR</span>-Human Resource Development Centre (CSIR‑HRDC), Ghaziabad from <strong>7 to 9 April 2026</strong>. The programme targeted CSIR scientists and technical officers, aiming to impart practical knowledge of cutting‑edge <span class="key-term" data-definition="Artificial Intelligence — technology enabling machines to mimic human cognition; increasingly used in scientific research and drug design (GS3: Technology & Innovation)">AI</span> tools that are reshaping <span class="key-term" data-definition="Drug Discovery — systematic process of identifying new therapeutic candidates, from target selection to clinical testing (GS3: Biotechnology)">Drug Discovery</span>.</p>
<h3>Key Developments</h3>
<ul>
<li>Inauguration by <strong>Prof. G. N. Sastry</strong> (Dept. of Biotechnology, IIT Hyderabad), <strong>Dr. T. S. Rana</strong> (Head, CSIR‑HRDC) and other dignitaries, highlighting AI’s transformative impact.</li>
<li>Lectures by experts from NIPER, IBAB, TCS, CSIR‑NEIST and IITs covering AI‑enabled <span class="key-term" data-definition="Target Identification — early stage of drug discovery where specific disease‑related molecules are pinpointed (GS3: Biotechnology)">Target Identification</span>, <span class="key-term" data-definition="Biomarker — measurable biological indicator used for disease diagnosis and drug response monitoring (GS3: Health & Medicine)">Biomarker</span> discovery, <span class="key-term" data-definition="Molecular Docking — computational method to predict binding orientation of a drug candidate with its target protein (GS3: Computational Chemistry)">Molecular Docking</span> & scoring, and <span class="key-term" data-definition="Bimolecular Simulation — computer‑based modeling of interactions between two molecules to study stability and dynamics (GS3: Computational Chemistry)">Bimolecular Simulation</span>.</li>
<li>Hands‑on sessions by <strong>Dr. Rajnish Kumar</strong> (IIT BHU), <strong>Dr. Firoz Khan</strong> (CSIR‑CIMAP) and <strong>Dr. Tarak Karmakar</strong> (IIT Delhi) providing practical exposure to AI‑driven computational pipelines.</li>
<li>Certificate distribution and valedictory address by <strong>Mrs. Preeti Chaudhary</strong>, acknowledging active participation.</li>
</ul>
<h3>Important Facts</h3>
<ul>
<li>Venue: CSIR‑HRDC, Ghaziabad.</li>
<li>Participants: CSIR scientists and technical officers (exact number not disclosed).</li>
<li>Organisers: Ministry of Science & Technology, CSIR‑HRDC.</li>
<li>Feedback: Highly positive, forming a template for future capacity‑building programmes.</li>
</ul>
<h3>UPSC Relevance</h3>
<p>The workshop underscores the growing convergence of <span class="key-term" data-definition="Artificial Intelligence — technology enabling machines to mimic human cognition; increasingly used in scientific research and drug design (GS3: Technology & Innovation)">AI</span> with biotechnology, a theme increasingly featured in GS‑3 (Science & Technology) and GS‑4 (Ethics of emerging tech). Understanding AI‑driven drug discovery helps aspirants grasp India’s strategic push for high‑end R&D, public‑private partnerships, and the role of institutions like <span class="key-term" data-definition="Council of Scientific & Industrial Research — India’s premier R&D organization under the Ministry of Science & Technology (GS1: Institutions)">CSIR</span> in translating research to health outcomes.</p>
<h3>Way Forward</h3>
<p>Building on the positive response, the Ministry plans to organize similar workshops across other CSIR labs, incorporate AI modules into regular training curricula, and foster collaborations with industry and academia to accelerate drug pipelines. Aspirants should monitor such initiatives as indicators of India’s innovation ecosystem and potential policy directions in health‑tech and biotech sectors.</p>